anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Perflutren
Trial phase: Phase 3
SMILES: FC(F)(F)C(F)(F)C(F)(F)F
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 103
Group description: Patients receiving contrast-enhanced ultrasound for diagnosis of chemoembolization response.

Ultrasound contrast agent (Contrast-enhanced ultrasound): Intravenous injection of ultrasound contrast agent followed by saline flush though an angiocatheter in the arm or hand.

Logiq E9 Scanner (Contrast-enhanced ultrasound): Ultrasound scanning using a commercial scanner with a C1-5-D broad-spectrum convex transducer followed by a RAB2-5-D broad-spectrum real-time 4D transducer.
Eligibility criteria:
Inclusion Criteria:

Patients >= 21 years of age
Patient capable of making informed decisions regarding his/her treatment
Scheduled for TACE treatment of a HCC mass (lesions reported as Liver Imaging Reporting and Data Systems 4B or 5 or Organ Procurement and Transplantation Network 5a or 5b)
Negative pregnancy test in a female of child-bearing age.
Have an HCC mass viewable on grayscale B-mode ultrasound.

Exclusion Criteria:

Females who are pregnant or nursing.
Patients not eligible or scheduled for TACE of a HCC mass.
Patients who have received an investigational drug in the 30 days before study drug administration, or will receive one within 72 h after their final CEUS exam.
Patients who have received prior radioembolization (Y90) of the lesion of interest.
Patients with known or suspected cardiac shunts.
Patients with pulmonary hypertension or unstable cardiopulmonary conditions.
Patients who are medically unstable, patients who are seriously or terminally ill, and patients whose clinical course is unpredictable. For example:
Patients with unstable occlusive disease (e.g., crescendo angina)
Patients with clinically unstable cardiac arrhythmias
Patients with uncontrolled congestive heart failure (NYHA Class IV)
Intervention: Treprostinil
Trial phase: Phase 2
ATC code: B01AC21
SMILES: [H][C@@]12Cc3c(cccc3OCC(=O)O)C[C@]1([H])[C@@H](CC[C@@H](O)CCCCC)[C@H](O)C2
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 14
Group description: Participants may receive either treprostinil or placebo at visit 2. They will receive the opposite at visit 3.

If receiving treprostinil, a 18mcg dose (3 breaths) will be administered using the Tyvaso® (treprostinil) inhalation system. Tyvaso® (treprostinil) is supplied in 2.9 mL clear ampules packaged as four ampules in a foil pouch. Frequency and duration- 3 times over 1 study visit: baseline, 1.5 hrs. post baseline and then again 2 hrs later following maximal exercise testing.

If receiving placebo, a dose of 3 breaths of placebo will be administered using the Tyvaso® (treprostinil) inhalation system. Placebo will be supplied in matching ampules to treprostinil. Volume will match that of treprostinil. Frequency and duration- 3 times over 1 study visit: baseline, 1.5 hrs. post baseline and then again 2 hrs later following maximal exercise testing.
Eligibility criteria:
Inclusion Criteria:

Patients age 18 years and older
Single ventricle patients status post Fontan procedure

Exclusion Criteria:

Clinically unstable: these are patients who are experiencing new cardiovascular symptoms such as worsening shortness of breath, new onset arrhythmia, uncontrolled heart failure, or evidence of clinically significant cirrhosis or renal failure.
Evidence of Fontan pathway or intra cardiac obstruction as identified on prior clinically indicated imaging studies (echocardiography and MRI);
Evidence of left or right systemic ventricular systolic dysfunction with an Ejection fraction of <40% on either echocardiogram or MRI from previously documented clinical data;
Presence of uncontrolled arrhythmias;
Unable to perform exercise testing for any reason or if deemed by the PI or designee that exercise testing would not be in the best interest of the participant
Currently pregnant and/or breastfeeding
Patient unable to provide informed consent
BMI > 30 mg/m2
Intervention: Acetaminophen
Trial phase: Phase 4
ATC code: N02AJ01 | N02AJ06 | N02AJ13 | N02AJ17 | N02BE01 | N02BE51 | N02BE71
SMILES: CC(=O)Nc1ccc(O)cc1
Sex: All
Age groups: Older Adult
Healthy volunteers: No
Participants at risk: 1
Group description: 1,000mg Acetaminophen po every 8 hours until discharge.

PO Acetaminophen: The patient will receive 1,000mg po Acetaminophen every 8 hours.
Eligibility criteria:
Inclusion Criteria:

Acute, isolated, unilateral femoral neck, intertrochanteric, and per trochanteric hip fractures confirmed by anteroposterior/lateral hip radiographs, computed tomography, or magnetic resonance imaging (MRI).
Age ≥ 65 years.
Low energy mechanism.
Hip fracture fixation performed within 48 hours of injury.
English speaking.
Anticipated medical optimization for operative fixation.
No other major trauma.

Exclusion Criteria:

Unable to provide informed consent (dementia, limited decision making capacity)
Admitted by medical service for significant co-morbidities
Retained hardware around the affected hip
Infection around the affected hip
Transfer patients with a length of stay > 24 hours at the transferring hospital
Known allergy to acetaminophen
Current use of narcotics
Receiving a regional anesthetic block at any point during the hospitalization
Known history of hepatic disease (hepatitis, cirrhosis)
Weight < 50kg
Prisoner
Involved in another clinical trial that would interfere with the intervention of this study
Intervention: Acetaminophen
Trial phase: Phase 4
ATC code: N02AJ01 | N02AJ06 | N02AJ13 | N02AJ17 | N02BE01 | N02BE51 | N02BE71
SMILES: CC(=O)Nc1ccc(O)cc1
Sex: All
Age groups: Older Adult
Healthy volunteers: No
Participants at risk: 1
Group description: 1,000mg Acetaminophen IV every 8 hours until the patient has received 3 doses post-operatively. Then 1,000mg Acetaminophen po every 8 hours until discharge.

IV Acetaminophen: The patient will receive 1,00mg IV Acetaminophen every 8 hours until 3 doses have been received post-operatively.
Eligibility criteria:
Inclusion Criteria:

Acute, isolated, unilateral femoral neck, intertrochanteric, and per trochanteric hip fractures confirmed by anteroposterior/lateral hip radiographs, computed tomography, or magnetic resonance imaging (MRI).
Age ≥ 65 years.
Low energy mechanism.
Hip fracture fixation performed within 48 hours of injury.
English speaking.
Anticipated medical optimization for operative fixation.
No other major trauma.

Exclusion Criteria:

Unable to provide informed consent (dementia, limited decision making capacity)
Admitted by medical service for significant co-morbidities
Retained hardware around the affected hip
Infection around the affected hip
Transfer patients with a length of stay > 24 hours at the transferring hospital
Known allergy to acetaminophen
Current use of narcotics
Receiving a regional anesthetic block at any point during the hospitalization
Known history of hepatic disease (hepatitis, cirrhosis)
Weight < 50kg
Prisoner
Involved in another clinical trial that would interfere with the intervention of this study
Intervention: Fentanyl
Trial phase: Phase 3
ATC code: N01AH01 | N01AH51 | N02AB03
SMILES: CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 42
Group description: Fentanyl 2 mcg/kg intranasally for one dose
Eligibility criteria:
Inclusion Criteria:

8 years to 17 years (up to the 18th birthday)
Presenting to emergency department with one or more extremity injuries
Visual analog scale score 35 mm or greater
Parent or legal guardian present and willing to provide written consent

Exclusion Criteria:

Received narcotic pain medication prior to arrival
Evidence of significant head, chest, abdomen, or spine injury
Glasgow coma score less than 15 or unable to self report pain score
Nasal trauma or aberrant nasal/airway anatomy
Active epistaxis
Allergy to ketamine, fentanyl or meperidine
Non-English speaking parent and/or child
History of psychosis
Postmenarchal female without a urine or serum assay documenting the absence of pregnancy
Brought in my juvenile detention center or in police custody
Pregnancy
Intervention: Finasteride
Trial phase: Phase 2
ATC code: D11AX10 | G04CA51 | G04CA55 | G04CB01 | G04CB51
SMILES: [H][C@@]12CC[C@@]3([H])NC(=O)C=C[C@]3(C)[C@@]1([H])CC[C@]1(C)[C@@H](C(=O)NC(C)(C)C)CC[C@@]21[H]
Sex: Male
Age groups: Adult
Healthy volunteers: No
Participants at risk: 12
Group description: Finasteride 1 mg tablet, orally, once daily for 24 weeks.
Eligibility criteria:
Inclusion Criteria:

Participant has androgenetic alopecia (AGA)
Participant agrees to maintain current hair care regimen, refraining from hair weaving, hair colorants or dyes and non-study hair growth products during the study.

Exclusion Criteria:

History of hair loss for reasons other than AGA
Scarring of the scalp or any condition or disease of the scalp, hair or hair shaft
Use of products within 6 months of study start used continuously for at least 1 month that could impact hair growth
Hair-weaving within 6 months
Use of hair colorants or dyes within 6 months.
Intervention: 8-Azabicyclo(3.2.1]octane, 3-(3,4-dichlorophenyl)-2-(methoxymethyl)-8-methyl-, (1R,2R,3S,5S)-
Trial phase: Phase 2
SMILES: COCC1C(c2ccc(Cl)c(Cl)c2)CC2CCC1N2C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 27
Group description: The initial dose of the NS2359 will be two mg once daily. Patients with difficult adverse events at the 2 mg dose will be allowed to reduce to 1 mg once daily. Subjects will participate in weekly cognitive behavioral relapse prevention psychotherapy from week 2 through week 9.

NS2359: NS2359 is a small molecule which inhibits the reuptake of dopamine, norepinephrine and serotonin with equal affinity.
Eligibility criteria:
Inclusion Criteria:

Male and females, 18-65 years old.
Meets diagnostic criteria (DSM-V) for current diagnosis of cocaine use disorder, moderate to severe, by semi-structured interview.
In the past 30 days, used no less than $100-worth of cocaine
Speaks, understands, and prints in English.

Exclusion Criteria:

Meets DSM-V criteria for substance use disorder, moderate to severe, for a substance other than cocaine, alcohol or nicotine. Subjects with comorbid alcohol use disorder will be accepted if their alcohol use disorder is not severe enough to require a medical alcohol detoxification.
Needs treatment with any psychoactive medications (with the exception of diphenhydramine or melatonin, if necessary, for sleep).
Meets current or lifetime DSM-V criteria for schizophrenia or any psychotic disorder, or organic mental disorder.
Has another Axis I psychiatric disorder that in the opinion of the physician will interfere with completion of the study or place the patient at heightened risk through participation in the trial.
Has evidence of a history of significant hematological, pulmonary, endocrine, cardiovascular, renal or gastrointestinal disease.
Use of an investigational medication in the 30 days prior to randomization.

Is female and has a positive pregnancy test, is contemplating pregnancy in the next 6 months, is nursing, or is not using effective contraception (if relevant).

-
Intervention: Methotrexate
Trial phase: Phase 4
ATC code: L01BA01 | L04AX03
SMILES: CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 122
Group description: Methotrexate (MTX) escalated to 20 - 25 mg or highest tolerable dose every week (ew) (MTX 20 - 25 mg or highest tolerable dose ew)
Eligibility criteria:
Inclusion Criteria:

PsA diagnosis established at least 4 weeks prior to the date of the Screening visit and confirmed by ClASsification of Psoriatic Arthritis (CASPAR) criteria
Not in MDA at the time of screening
Has 3 or more tender and 3 or more swollen joints
Treated with methotrexate 15 mg (weekly) for at least 4 weeks

Exclusion Criteria:

Contraindications to adalimumab therapy and/or known hypersensitivity to adalimumab or its excipients
History of methotrexate intolerance/toxicity
Medical conditions(s) precluding methotrexate dose increase above 15 mg
Had prior exposure to any tumor necrosis factor (TNF) inhibitor, other mechanism of action biologic DMARD (bDMARD) or any systemic biologic agent in general
Intervention: Methotrexate
Trial phase: Phase 4
ATC code: L01BA01 | L04AX03
SMILES: CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 15
Group description: Participants achieving MDA at Week 16 on MTX escalated to 20 -25 mg or highest tolerable dose ew, continued with the same MTX dose (MTX 20 - 25 mg or highest tolerable dose ew)
Eligibility criteria:
Inclusion Criteria:

PsA diagnosis established at least 4 weeks prior to the date of the Screening visit and confirmed by ClASsification of Psoriatic Arthritis (CASPAR) criteria
Not in MDA at the time of screening
Has 3 or more tender and 3 or more swollen joints
Treated with methotrexate 15 mg (weekly) for at least 4 weeks

Exclusion Criteria:

Contraindications to adalimumab therapy and/or known hypersensitivity to adalimumab or its excipients
History of methotrexate intolerance/toxicity
Medical conditions(s) precluding methotrexate dose increase above 15 mg
Had prior exposure to any tumor necrosis factor (TNF) inhibitor, other mechanism of action biologic DMARD (bDMARD) or any systemic biologic agent in general
Intervention: Metformin
Trial phase: Phase 2
ATC code: A10BA02 | A10BD02 | A10BD03 | A10BD05 | A10BD07 | A10BD08 | A10BD10 | A10BD11 | A10BD13 | A10BD14 | A10BD15 | A10BD16 | A10BD17 | A10BD18 | A10BD20 | A10BD22 | A10BD23 | A10BD25 | A10BD26 | A10BD27
SMILES: CN(C)C(=N)NC(=N)N
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 2
Group description: Metformin added to standard of care treatment for all patients

Metformin: given in addition to standard of care treatment
Eligibility criteria:
Inclusion Criteria:

Male or female ≥ 18 years of age

Diagnosis of DLBCL as documented by medical records and with histology based on criteria established by the World Health Organization

subtyping is required for DLBCL
c-myc+ defined as presence of c-myc breaks by karyotype/FISH and/or IHC ≥ 40%; this includes double hits (with bcl-2 breaks found using cytogenetics/FISH) and/or double expressors (with bcl-2 protein expression ≥ 70% by IHC); increased copy number in itself is not considered positivity for c-myc
No prior therapy for diagnosis of DLBCL with exception of steroids
Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0- 2 (Appendix B)
Life expectancy of at least 6 months
No history of medication dependent diabetes mellitus
No evidence of acute or chronic metabolic acidosis (baseline venous lactate ≤ 4)

Exclusion Criteria

Patient already on any class of anti-diabetic medication including metformin, insulin analogues, sulfonylureas, thiazolidinediones (TZDs) and the incretin-based therapies or clear need for therapeutic intervention based on fasting blood glucose
Known histological transformation from indolent non-Hodgkin Lymphoma (iNHL) or chronic lymphocytic leukemia (CLL) to an aggressive form of non-Hodgkin's lymphoma (NHL) (ie, Richter transformation)
Burkitt and/or precursor lymphoblastic leukemia/lymphoma.
Presence of known intermediate- or high-grade myelodysplastic syndrome
History of an active of treated non-lymphoid malignancy within the last 3 years excluding basal cell and squamous cell skin cancers
Evidence of ongoing systemic bacterial, fungal, or viral infection at the time of start of study drug.
Subjects who have currently active hepatic or biliary disease (with exception of patients with Gilbert's syndrome, asymptomatic gallstones, liver involvement with NHL or stable chronic liver disease per investigator assessment)
Renal insufficiency with creatinine > 1.5 x upper limit of normal (ULN) OR creatinine clearance of < 45 ml/min as calculated by the Cockcroft-Gault method
CNS or leptomeningeal involvement of lymphoma
HIV positive
Ongoing inflammatory bowel disease
Ongoing alcohol or drug addiction
Pregnancy or breastfeeding
History of prior allogeneic bone marrow progenitor cell or solid organ transplantation -
Intervention: Tadalafil
Trial phase: Phase 2
ATC code: C02KX52 | C02KX54 | G04BE08 | G04CA54 | G04CB51
SMILES: [H][C@]12Cc3c([nH]c4ccccc34)[C@@H](c3ccc4c(c3)OCO4)N1C(=O)CN(C)C2=O
Sex: All
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 61
Group description: Subjects will be randomized to one of two arms. 100 obese adult subjects will be randomized to the Tadalafil arm following the screening visit. Beginning at their baseline visit, they will receive an oral daily dose of Tadalafil (20mg) that they will take for 12 weeks (through their completion of the study). After randomization has occurred, the active comparator subjects will undergo the following visit protocol: baseline visit (two half-days), an interim visit (6 weeks post-baseline), and a 12-week visit (two half-days).

Tadalafil: Tadalafil is an FDA approved, clinically-available drug that inhibits the enzyme phosphodiesterase type 5A (PDE5). Subjects who are randomized to this arm will be provided with 20mg of Tadalafil to take every day for 12 weeks, beginning at their baseline visit.
Eligibility criteria:
Inclusion Criteria:

Adults (ages 21-50)
Obesity (BMI ≥ 30 kg/m2)
Prediabetes on oral glucose tolerance test.

Exclusion Criteria:

Age <21 or > 50
BMI < 30 kg/m2
Systolic blood pressure (SBP) < 100, > 150 mmHg
Current anti-hypertensive medication use, including diuretics
Current use of organic nitrates
Current use of PDE-5 inhibitors (sildenafil, tadalafil, vardenafil)
History of reaction to PDE-5 inhibitors
Known HIV infection
Use of medications that strongly alter CYP3A4 activity
History of myocardial infarction, angina, uncontrolled cardiac arrhythmia, stroke, transient ischemic attack, or seizure
Known non-arteritic ischemic optic retinopathy (NAIOR)
History of hearing loss
Estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73 m2 by the modified diet in renal disease (MDRD) equation
Hepatic transaminase (AST and ALT) levels greater than three times the upper limit of normal
Known pregnancy or breastfeeding or those unwilling to avoid pregnancy during the course of the study
History of priapism
Use in excess of four alcoholic drinks daily
History of diabetes mellitus or use of anti-diabetic medications
Known anemia (men, Hct < 38% and women, Hct <36%)
Menopause
Inability to exercise on a bicycle
Weight > 300 pounds
Intervention: Avycaz
Trial phase: Phase 1
SMILES: CC(C)(ON=C(C(=O)NC1C(=O)N2C(C(=O)[O-])=C(C[n+]3ccccc3)CSC12)c1csc(N)n1)C(=O)O.NC(=O)C1CCC2CN1C(=O)N2OS(=O)(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 10
Group description: Ceftazadime/avibactam 2500 mg (1250 mg for CrCl 31-50 mL/min) IV over 120 minutes, every 8 hours [other antibiotics can also be administered as needed]. Patients will receive at least 3 doses (steady-state) of Avycaz prior to obtaining serum samples.

Ceftazidime/avibactam: Ceftazadime/avibactam dosing in ICU patients
Eligibility criteria:
Inclusion Criteria:

Adult (≥18y/o) patients with a medical or post-surgical infection such as skin/soft tissue infections, urinary infections, IA infections and pneumonia (including VAP)
Patients requiring intensive care (critically ill patients) in the med/surg ICU (APACHE II score ≥ 15)
Patients prescribed Avycaz for their infection will receive FDA recommended dosages and times of administration
Written informed consent

Exclusion Criteria:

Pregnant Patients, patients older than 90 y/o, those with CrCl < 30 mL/min, patients with a BMI > 45 Kg/m2, patients unable to provide serum samples, and those with the risk of imminent death during the study
Intervention: Clarithromycin
Trial phase: Not Applicable
ATC code: A02BD04 | A02BD05 | A02BD06 | A02BD07 | A02BD09 | A02BD11 | A02BD12 | A02BD14 | J01FA09
SMILES: [H][C@]1(O[C@H]2[C@H](C)[C@@H](O[C@]3([H])O[C@H](C)C[C@H](N(C)C)[C@H]3O)[C@](C)(OC)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]2C)C[C@@](C)(OC)[C@@H](O)[C@H](C)O1
Sex: All
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 20
Group description: 20 subjects that received one-stage full-mouth ultrasonic debridement (FMUD) associated with clarithromycin (500 mg - 12/12 hours) for 3 days.

Clarithromycin: Use of 500mg of Clarithromycin twice a day for 3 days

One-stage full-mouth ultrasonic debridement (FMUD): One session of Periodontal debridement using ultrasonic device.
Eligibility criteria:
Inclusion Criteria:

diagnosis of Generalized Aggressive Periodontitis
presence of ≥20 teeth
presence of ≥ 6 sites presenting probing depth (PD) ≥5mm with bleeding on probing (BOP) and ≥2 sites with PD ≥7mm (including incisors and first molars, in addition to two other non-contiguous teeth between them)
good general health
<35 years of age
agree to participate in the study and sign a written consent

Exclusion Criteria:

pregnant or lactating
suffering from any other systemic disease (e.g. cardiovascular, diabetes, blood dyscrasias, immunodeficiency, etc) which could alter the course of periodontal disease
received antimicrobials in the previous 6 months
taking long-term anti-inflammatory drugs
received a course of periodontal treatment within the last 12 months
smoked
Intervention: Acetaminophen
Trial phase: Phase 4
ATC code: N02AJ01 | N02AJ06 | N02AJ13 | N02AJ17 | N02BE01 | N02BE51 | N02BE71
SMILES: CC(=O)Nc1ccc(O)cc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 47
Group description: Patients 50kg or more will receive either 1000mg IV acetaminophen with the first dose given preoperatively in the holding area followed by re-dosing every four hours from that point up to a maximum of 4 doses or 4000mg in 24 hours. Patients <50 kg will receive 12.5mg/kg to a maximum of 75 mg /per kg/per day as per the label dose with repeat dosing Q4 hours. Blinded medication will be prepared by research pharmacist in 100mL of normal saline

Acetaminophen: patients 50kg or more receive1000mg in 100milliliters of normal saline every 4 hours to a maximum dose 4000mg/24 hours. <50kg receive 12.5mg/kg to a maximum of 75mg/kg/24 hours.
Eligibility criteria:
Inclusion Criteria:

Undergoing ambulatory laparoscopic cholecystectomy.
American Society of Anesthesiologists physical status 1, 2 or 3.-

Exclusion Criteria -

Cognitively impaired (by history) and unable or unwilling to consent
Chronic steroid or opioid user (as prescribed for a chronic systemic illness)
Parturient or nursing mother. Patients who have been informed by a physician that they have liver or kidney disease